(firstQuint)HL2351 CAPS Phase II Study.

 This trial enrolls patients with CAPS being on stable dose of anakinra daily and then switch over HL2351 given once weekly.

 It consists of 4 phases, 6-week screening, single dose PK, 6-month multiple dose, and 18-month extension phase.

.

 HL2351 CAPS Phase II Study@highlight

This is an open label, single arm trial to evaluate the efficacy, safety, and pharmacokinetics of HL2351 in patients with cryopyrin associated periodic syndromes (CAPS).

